|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RRNAD1 |
Gene summary for RRNAD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RRNAD1 | Gene ID | 51093 |
| Gene name | methyltransferase like 25B | |
| Gene Alias | C1orf66 | |
| Cytomap | 1q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0000154 | UniProtAcc | Q96FB5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51093 | RRNAD1 | LZE4T | Human | Esophagus | ESCC | 1.59e-03 | 3.59e-02 | 0.0811 |
| 51093 | RRNAD1 | LZE7T | Human | Esophagus | ESCC | 1.09e-06 | 2.54e-01 | 0.0667 |
| 51093 | RRNAD1 | LZE20T | Human | Esophagus | ESCC | 9.45e-04 | 7.84e-02 | 0.0662 |
| 51093 | RRNAD1 | LZE22T | Human | Esophagus | ESCC | 1.11e-02 | 1.29e-01 | 0.068 |
| 51093 | RRNAD1 | LZE24T | Human | Esophagus | ESCC | 9.79e-14 | 3.57e-01 | 0.0596 |
| 51093 | RRNAD1 | LZE21T | Human | Esophagus | ESCC | 2.20e-03 | 1.19e-01 | 0.0655 |
| 51093 | RRNAD1 | LZE6T | Human | Esophagus | ESCC | 2.41e-05 | 3.05e-01 | 0.0845 |
| 51093 | RRNAD1 | P1T-E | Human | Esophagus | ESCC | 2.34e-13 | 4.16e-01 | 0.0875 |
| 51093 | RRNAD1 | P2T-E | Human | Esophagus | ESCC | 2.57e-20 | 3.07e-01 | 0.1177 |
| 51093 | RRNAD1 | P4T-E | Human | Esophagus | ESCC | 4.25e-17 | 2.58e-01 | 0.1323 |
| 51093 | RRNAD1 | P5T-E | Human | Esophagus | ESCC | 1.12e-11 | 1.89e-01 | 0.1327 |
| 51093 | RRNAD1 | P8T-E | Human | Esophagus | ESCC | 2.55e-13 | 1.75e-01 | 0.0889 |
| 51093 | RRNAD1 | P9T-E | Human | Esophagus | ESCC | 5.83e-17 | 3.83e-01 | 0.1131 |
| 51093 | RRNAD1 | P10T-E | Human | Esophagus | ESCC | 4.45e-20 | 2.10e-01 | 0.116 |
| 51093 | RRNAD1 | P11T-E | Human | Esophagus | ESCC | 3.53e-12 | 2.31e-01 | 0.1426 |
| 51093 | RRNAD1 | P12T-E | Human | Esophagus | ESCC | 1.20e-19 | 1.43e-01 | 0.1122 |
| 51093 | RRNAD1 | P15T-E | Human | Esophagus | ESCC | 5.33e-08 | 1.56e-01 | 0.1149 |
| 51093 | RRNAD1 | P16T-E | Human | Esophagus | ESCC | 4.56e-13 | 1.99e-01 | 0.1153 |
| 51093 | RRNAD1 | P17T-E | Human | Esophagus | ESCC | 5.45e-11 | 2.66e-01 | 0.1278 |
| 51093 | RRNAD1 | P20T-E | Human | Esophagus | ESCC | 1.28e-07 | 1.81e-01 | 0.1124 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RRNAD1 | SNV | Missense_Mutation | c.1314T>G | p.His438Gln | p.H438Q | Q96FB5 | protein_coding | tolerated(0.77) | benign(0.003) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RRNAD1 | SNV | Missense_Mutation | c.530N>C | p.Leu177Ser | p.L177S | Q96FB5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| RRNAD1 | SNV | Missense_Mutation | c.111N>G | p.Ile37Met | p.I37M | Q96FB5 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| RRNAD1 | SNV | Missense_Mutation | novel | c.1013N>G | p.Thr338Ser | p.T338S | Q96FB5 | protein_coding | tolerated(0.15) | benign(0.018) | TCGA-GM-A3XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
| RRNAD1 | insertion | Frame_Shift_Ins | novel | c.373_374insCCCTTTTTTTT | p.Phe126LeufsTer24 | p.F126Lfs*24 | Q96FB5 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| RRNAD1 | insertion | Frame_Shift_Ins | novel | c.375_376insGCTGACATAAATAATATTTCTT | p.Phe126AlafsTer19 | p.F126Afs*19 | Q96FB5 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| RRNAD1 | insertion | Nonsense_Mutation | novel | c.1324_1325insAAGTCCCAGCCCCAACATCTTCTGGGCCTAGCTAATCACTGTTG | p.Leu442GlnfsTer12 | p.L442Qfs*12 | Q96FB5 | protein_coding | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
| RRNAD1 | insertion | In_Frame_Ins | novel | c.1382_1383insACCACCACA | p.Met461delinsIleProProGln | p.M461delinsIPPQ | Q96FB5 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| RRNAD1 | SNV | Missense_Mutation | novel | c.1383N>T | p.Met461Ile | p.M461I | Q96FB5 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RRNAD1 | SNV | Missense_Mutation | c.1015N>G | p.His339Asp | p.H339D | Q96FB5 | protein_coding | deleterious(0) | possibly_damaging(0.858) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |